QUOTE AND NEWS
Benzinga  Apr 15  Comment 
In a report published Wednesday, JP Morgan analysts initiated coverage of Akorn, Inc. (NASDAQ: AKRX) with a price target of $61. "Akorn is a niche generic manufacturer with capabilities in attractive, high barrier-to-entry markets (injectables,...
Benzinga  Apr 8  Comment 
Deutsche Bank issued a company note on Akorn, Inc. (NASDAQ: AKRX) initiating coverage on the company. Deutsche Bank rates Akorn as a Buy with a $55 price target. Analysts Gregg Gilbert and Greg Fraser wrote, "For a midcap specialty generics...
TheStreet.com  Mar 18  Comment 
NEW YORK (TheStreet) -- Shares of Akorn are up 10.31% to $48.36 in afternoon trading today after the company filed its 2014 annual report after the closing bell yesterday after requesting an extension. It restated results for the second...
Benzinga  Mar 13  Comment 
Akorn, Inc. (NASDAQ: AKRX) gained more than 6 percent to $44.04 in the extended session Friday. The shares are off about 17 percent since posting quarterly results earlier this week. Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) picked up more...
Benzinga  Mar 11  Comment 
Express Inc. (NYSE: EXPR) gained 7.36% to $16.05 in pre-market trading after the company reported better-than-expected financial results for the fourth quarter. American Realty Capital Properties, Inc.(NASDAQ: ARCP) shares rose 6.74% to $9.96...
Benzinga  Mar 11  Comment 
Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced several generic product launches that build on Akorn's commitment to serve the company's specialty generic customers and patients. Adenosine Injection....
TheStreet.com  Mar 10  Comment 
NEW YORK (TheStreet) -- Shares of Akorn are down 14.31% to $44.42 today as the company reaffirmed its 2015 guidance issued on February 26, calling for revenue of between $960 million and $980 million, and adjusted diluted earnings per share of...





You may also be interested in articles related to Akorn (AKRX):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki